Justin Schreiber Sells 50,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $7.55, for a total value of $377,500.00. Following the completion of the transaction, the chief executive officer now owns 2,653,715 shares of the company’s stock, valued at $20,035,548.25. The trade was a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Justin Schreiber also recently made the following trade(s):

• On Thursday, January 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The shares were sold at an average price of $5.19, for a total value of $129,750.00.
• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The shares were sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Stock Performance

NASDAQ:LFMD opened at $5.46 on Monday. The stock’s fifty day moving average is $5.69 and its 200 day moving average is $5.40. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The firm has a market capitalization of $236.47 million, a PE ratio of -8.53 and a beta of 1.50.

Institutional Trading of LifeMD

Several hedge funds and other institutional investors have recently bought and sold shares of LFMD. SG Americas Securities LLC purchased a new stake in LifeMD during the 3rd quarter valued at $70,000. CWM LLC purchased a new stake in LifeMD in the third quarter worth $59,000. Los Angeles Capital Management LLC increased its stake in LifeMD by 852.6% in the third quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock worth $637,000 after purchasing an additional 108,822 shares during the period. Royce & Associates LP increased its stake in LifeMD by 14.6% in the third quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock worth $4,721,000 after purchasing an additional 114,710 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in LifeMD by 6.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 765,916 shares of the company’s stock worth $4,013,000 after purchasing an additional 48,201 shares during the period. Hedge funds and other institutional investors own 35.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on LFMD. Mizuho began coverage on LifeMD in a research report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price for the company. Lake Street Capital began coverage on LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of LifeMD in a research report on Monday, November 11th. Finally, KeyCorp lowered their target price on LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, LifeMD presently has a consensus rating of “Moderate Buy” and an average price target of $11.14.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.